Mkb 10 neoplasm disease codes. C00-C97 Malignant neoplasms
Some malignant tumors are poorly curable and often lead to the death of the patient. However, in many cases a cure is possible. An important factor determining the success of treatment is early diagnosis. The outcome of treatment is largely determined by the degree of development of the tumor process, its stage. In the early stages, the chances are very high, so you should constantly monitor your health using the services of professional doctors. At the same time, you can’t waste time trying to be cured with the help of alternative medicine, ignoring modern methods of treatment, this will only aggravate your condition and complicate subsequent treatment.
The following treatments are currently being used:
Removal of the tumor. Since tumor cells can also be found outside the tumor, it is removed with a margin. For example, in breast cancer, the entire breast is usually removed, as well as the axillary and subclavian lymph nodes. If, nevertheless, there are tumor cells outside the removed organ or part of it, the operation does not prevent them from forming metastases. Moreover, after removal of the primary tumor, the growth of metastases is accelerated. However, this method often cures malignant tumors (such as breast cancer) if the operation is done early enough. Surgical removal of the tumor can be carried out both with traditional cold instruments and with the use of new instruments (laser, radiofrequency knife, ultrasonic scalpel, etc.). For example, removal of laryngeal cancer (stages 1-2) with a laser with direct laryngoscopy allows the patient to maintain an acceptable voice and avoid tracheostomy, which is far from always possible with traditional open surgeries (not endoscopic). The laser beam, compared to a conventional scalpel, reduces bleeding during surgery, destroys tumor cells in the wound, and provides better wound healing in the postoperative period.
Chemotherapy. Drugs are used that target rapidly dividing cells. Drugs can suppress DNA duplication, interfere with the division of the cell membrane into two. However, in addition to tumor cells, many healthy ones, for example, stomach epithelial cells, intensively and rapidly divide in the body. They are also damaged by chemotherapy. Therefore, chemotherapy leads to severe side effects. When chemotherapy is stopped, healthy cells regenerate. In the late 1990s, new drugs came on the market that attacked the proteins of tumor cells with little or no damage to normal dividing cells. Currently, these drugs are used only for certain types of malignant tumors.
Radiotherapy. Radiation kills malignant cells by damaging their genetic material, while healthy cells suffer less damage. For irradiation, gamma radiation (short-wavelength photons, they penetrate to any depth), neutrons (penetrate only to a limited depth) and electrons (penetrate to a very shallow depth; used to treat malignant tumors of the skin and subcutaneous cells) are used.
Cryotherapy.
Photodynamic therapy with drugs that can destroy cells of a malignant tumor under the influence of a light flux of a certain wavelength (Photohem, "photoditazin", radachlorin, photosens, alasens, photolon, etc.).
hormone therapy. Cells of malignant tumors of some organs react to hormones, which is used. So, for prostate cancer, the female hormone estrogen is used, for breast cancer - drugs that suppress the action of estrogen, glucocorticoids - for lymphomas. Hormone therapy is a palliative treatment: it cannot destroy the tumor on its own, but it can prolong life or improve the chances of a cure when combined with other methods. As a palliative treatment, it is effective: in some types of malignant tumors, it prolongs life by 3-5 years.
Immunotherapy. The immune system seeks to destroy the tumor. However, due to a number of reasons, it is often unable to do so. Immunotherapy helps the immune system fight the tumor by making it attack the tumor more effectively or by making the tumor more susceptible. Sometimes interferon is used for this.
Combined treatment. Each of the methods of treatment separately (except palliative) can destroy a malignant tumor, but not in all cases. To improve the effectiveness of treatment, a combination of two or more methods is often used.
To alleviate the suffering of terminal patients, drugs are used (to combat pain) and psychiatric drugs (to combat depression and fear of death).
Neoplastic diseases are most fully described in the current International Classification of Diseases of the 10th revision, adopted in Geneva in 1992.
Class II "Neoplasms" contains 146 headings. Compared to previous editions, almost 20 additional localizations have been introduced, which are now identified at the level of 3-digit rubrics. These are such localizations as the palate, parotid salivary gland, tonsils, rectum, rectosigmoid junction, gallbladder, vagina, vulva, penis, adrenal gland, which were previously identified only at the level of the fourth sign.
When working with ICD-10 adhere to the following rules. The first axis in coding is the nature of the neoplasm (malignant, benign, in situ, indeterminate, secondary); the second axis is localization. Neoplasm codes are grouped according to the nature of the neoplasm in the following sequence:
COO-C75 - malignant neoplasms of specified localizations, which are designated as primary or presumably primary, except for neoplasms of lymphoid, hematopoietic and related tissues.
C76-C80 - malignant neoplasms of ill-defined, secondary and unspecified localizations.
C81-C96 - malignant neoplasms of lymphoid, hematopoietic and related tissues, which are designated as primary or presumably primary.
D00-D09 Neoplasms in situ.
D10-D36 - benign neoplasms.
D37-D48 - neoplasms of an indefinite and unknown nature.
Malignant neoplasms belonging to the COO-C75 rubrics are coded by localization, the fourth character of the code (after the dot) subdivides most of the rubrics into narrower localizations within the general one. For example, malignant neoplasms of the colon are classified under C18, the fourth character after the dot specifies the location of the hepatic flexure - C18.3, sigmoid colon - C18.7, appendix - C18.1.
Malignant neoplasms of the lymphatic and hematopoietic tissues are classified under C81-C96, which include lymphogranulomatosis, non-Hodgkin's lymphomas, malignant immunoproliferative conditions, multiple myeloma, and leukemias. The fourth sign indicates the cellular specificity and degree of malignancy of the process. For example, lymphogranulomatosis, mixed cell variant - C81.2, lymphogranulomatosis with nodular sclerosis - C81.1, acute lymphocytic leukemia - C91.0, chronic lymphocytic leukemia - C91.1.
There are rubrics in which 4-digit codes are used, depending on one or another terminology used by codifiers. When describing malignant neoplasms of the esophagus, one can speak of damage to the cervical (C15.0), thoracic (C15.1), abdominal (C15.2) departments or upper (C15.3), middle (C15.4), lower (C15.5 ) thirds of the esophagus.
A malignant neoplasm that can be assigned to two or more subcategories within a 3-digit category and whose site of origin cannot be determined is classified in the subcategory with the fourth character 8. For example, pancreatic cancer that spreads to the head and body of the gland should be classified under C25.8. When the malignant tumor is known to have originated in the head of the pancreas and has spread to the body, code to C25.0 (cancer of the head of the pancreas).
There are subcategories designed to code for malignant neoplasms that can be assigned to more than one 3-character category within a particular system. For example, a neoplasm involving the stomach and colon, without specifying the primary site, is coded as C26.8 (lesion of the digestive system beyond one localization).
Those neoplasms that cannot be classified according to the above recommendations should be assigned to the appropriate subheading of heading C76. Thus, the diagnosis of a malignant neoplasm of the chest should be coded as C76.1, soft tissue sarcoma of the head as C76.0.
Categories C77-C79 include conditions where a patient has metastatic lesions without an established primary tumor. For example, a diagnosis of "metastases of a malignant tumor in the mediastinal lymph nodes without an established primary source" should be coded as C77.1 (intrathoracic lymph nodes).
If the diagnosis does not specify the localization and the subsequent analysis of the medical history does not provide the necessary information, use the heading C80 - malignant neoplasms without specifying the localization. This includes primary and secondary neoplasms with common diagnoses such as cancer, sarcoma, carcinoma, carcinomatosis, malignant cachexia.
An important section of the ICD-10 is the section of morphological codes, which takes into account the nature of the neoplasm and its histological type. Morphological codes consist of the letter M, followed by a 4-digit characteristic of the histological type of the tumor and the nature of the neoplasm, indicated through a dividing line (Table 1).
Tab. 1. Correlations between the code of the nature of the neoplasm and the headings of class II "Neoplasms"
| Neoplasm character code | Categories | Term |
| /0 | D10-D36 | Benign neoplasms |
| /1 | D37-D48 |
Neoplasms of uncertain or unknown nature |
| /2 | D00-D09 | Neoplasms in situ |
| /3 | COO-С75 | Malignant neoplasms of specified localizations |
| С81-С96 | primary or presumably primary | |
| /6 | С76-С80 | Malignant neoplasms of a secondary or presumably secondary nature |
For example, lung cancer is coded as M8010/3, lung adenoma is designated M8140/0, adenocarcinoma in situ from an adenomatous polyp is M8210/2, granulosa cell tumor is M8620/1, and metastatic adenocarcinoma is M8140/6.
From a clinical point of view, in the classification of malignant tumors, special attention is paid to the degree of prevalence of the disease.
The prevalence of the tumor process is characterized by three main parameters: the size of the primary tumor, the presence of metastases in regional lymph nodes and the presence of distant metastases. The summary characteristic of the state of all three components, taking into account the peculiarities of the process within each of them, gives modafinil online an idea of the stage of the disease. In the clinical aspect, the division into stages is based on the different course and outcome of localized and widespread malignant processes. The main goal of the International classification of malignant neoplasms by the prevalence of the process is to develop a methodology for the uniform presentation of clinical data. Uniform evaluation criteria contribute to the exchange of objective information between medical centers and further study of the problem of cancer.
Diagnosis code C00-D48 includes 4 clarifying diagnoses (ICD-10 headings):
- C00-C97 - Malignant neoplasms
Contains 15 blocks of diagnoses. - D00-D09 Neoplasms in situ
Contains 9 blocks of diagnoses.
Includes: Bowen's disease erythroplasia morphological codes with pattern code /2 erythroplasia Queyrat. - D10-D36 - Benign neoplasms
Contains 27 blocks of diagnoses.
Included: morphological codes with pattern code /0. - D37-D48 - Neoplasms of uncertain or unknown nature
Contains 12 blocks of diagnoses.
Explanation of the disease with the code C00-D48 in the MBK-10 reference book:
Notes
- Malignant neoplasms, primary, ill-defined and unspecified sites
Categories C76-C80 include malignant neoplasms with an ill-defined primary site or those defined as "disseminated", "disseminated" or "spread" without indication of the primary site. In both cases, the primary localization is considered as unknown. - functional activity
Class II is classified as neoplasms, regardless of the presence or absence of functional activity in them. If it is necessary to clarify the functional activity associated with a particular neoplasm, an additional code from class IV can be used. For example, catecholamine-producing adrenal malignant pheochromocytoma is coded under C74 with an additional code E27.5; basophilic pituitary adenoma with Itsenko-Cushing's syndrome is coded by heading D35.2 with an additional code E24.0. - Morphology
There are a number of large morphological (histological) groups of malignant neoplasms: caracinomas, including squamous and adenocarcinomas; sarcomas; other soft tissue tumors, including mesothelioma; lymphomas (Hodgkin's and non-Hodgkin's); leukemia; other refined and localization-specific types; unspecified cancers. The term "cancer" is generic and can be used for any of the above groups, although it is rarely used in relation to malignant neoplasms of the lymphoid, hematopoietic and related tissues. The term "carcinoma" is sometimes incorrectly used as a synonym for the term "cancer".
In class II, neoplasms are classified mainly by localization within broad groupings based on the nature of the course. In exceptional cases, morphology is indicated in the headings and subheadings.
For those wishing to identify the histological type of neoplasm on p. 577-599 (vol. 1, part 2) provides a general list of individual morphological codes. Morphological codes are taken from the second edition of the International Classification of Diseases in Oncology (ICD-O), which is a biaxial classified system that provides independent coding of neoplasms by topography and morphology.
Morphological codes have 6 characters, of which the first four determine the histological type, the fifth indicates the nature of the course of the tumor (malignant primary, malignant secondary, i.e. metastatic, in situ, benign, indefinite), and the sixth character determines the degree of differentiation of solid tumors and is also used as a special code for lymphomas and leukemias. - Use of subcategories in class II
Attention is drawn to the special use in this class of the subcategory marked.8 (see note 5). Where it is necessary to distinguish a subcategory for the group "others", a subcategory is usually used.7. - Malignant neoplasms extending beyond one site and the use of a subcategory with a fourth character.8 (lesion extending beyond one or more of the specified sites)
Headings C00-C75 classify primary malignant neoplasms according to their site of origin. Many three-character rubrics are further subdivided into subcategories according to the different parts of the organs concerned. A neoplasm that involves two or more contiguous sites within a three-character rubric, and whose site of origin cannot be determined, should be classified in a subcategory with a fourth character.8 (a lesion extending beyond one or more of the above sites), unless such a combination is specifically indexed elsewhere headings. For example, carcinoma of the esophagus and stomach is coded C16.0 (cardia), while carcinoma of the tip and underside of the tongue should be coded as C02.8. On the other hand, carcinoma of the tip of the tongue involving the lower surface of the tongue should be coded to C02.1 because the site of origin (in this case, the tip of the tongue) is known.
The term "lesion extending beyond one or more of the above locations" implies that the areas involved are contiguous (one continues the other). The subcategory numbering sequence often (but not always) corresponds to the anatomical neighborhood of the sites (eg bladder C67.-), and the coder may be forced to refer to anatomical reference books to determine the topographic relationship.
Sometimes the neoplasm goes beyond the localizations indicated by three-digit rubrics within one organ system. The following subcategories are provided for coding such cases:
C02.8 Tongue involvement extending beyond one or more of the above locations
C08.8 Involvement of major salivary glands extending beyond one or more of the above sites
C14.8 Involvement of lips, oral cavity and pharynx extending beyond one or more of the above sites
C21.8 Involvement of rectum, anus [anus] and anal canal extending beyond one or more of the above locations
C24.8 Biliary tract disorder extending beyond one or more of the above sites
C26.8 Gastrointestinal disorder extending beyond one or more of the above sites
C39.8 Involvement of respiratory and thoracic organs extending beyond one or more of the above sites
C41.8 Bone and articular cartilage disorder extending beyond one or more of the above locations
C49.8 Connective and soft tissue disorder extending beyond one or more of the above locations
C57.8 Disorders of female genital organs extending beyond one or more of the above sites
C63.8 Disorder of male genital organs extending beyond one or more of the above sites
C68.8 Urinary disorders extending beyond one or more of the above sites
C72.8 Disorders of the brain and other parts of the central nervous system extending beyond one or more of the above locations
An example would be carcinoma of the stomach and small intestine, which would be coded to C26.8 (disease of the digestive system extending beyond one or more of the above sites). - Malignant neoplasms of ectopic tissue
Malignancies of ectopic tissue should be coded according to the site mentioned, eg ectopic malignancy of the pancreas should be coded as pancreatic, unspecified (C25.9). - Use of the Alphabetical Index when coding neoplasms
When coding neoplasms, in addition to their localization, the morphology and nature of the course of the disease should be taken into account and, first of all, it is necessary to refer to the Alphabetical Index for a morphological description. Volume 3's introductory pages include general instructions for using the Alphabetical Index. In order to ensure the correct use of the rubrics and subcategories of Class II, special indications and examples relating to neoplasms should be taken into account. - Use of the second edition of the International Classification of Diseases in Oncology (ICD-0)
For some morphological types, class II provides a rather narrow topographic classification, or none at all. ICD-0 topographical codes are used for all neoplasms with essentially the same three- and four-digit rubrics used in Class II for malignant neoplasms (C00-C77, C80), thereby providing greater localization accuracy for other neoplasms [malignant secondary ( metastatic), benign, in situ, uncertain or unknown].
Thus, institutions interested in determining the location and morphology of tumors (such as cancer registries, cancer hospitals, pathology departments, and other services specialized in oncology) should use ICD-0.
This class contains the following broad groups of neoplasms:
- C00-C75 Malignant neoplasms of specified locations, which are designated as primary or presumably primary, except for neoplasms of lymphoid, hematopoietic and related tissues
- C00-C14 Lips, oral cavity and pharynx
- C15-C26 Digestive organs
- C30-C39 Respiratory and thoracic organs
- C40-C41 Bones and articular cartilage
- C43-C44 Skin
- C45-C49 Mesothelial and soft tissues
- C50 Mammary gland
- C51-C58 Female reproductive organs
- C60-C63 Male reproductive organs
- C64-C68 Urinary tract
- C69-C72 Eyes, brain and other parts of the central nervous system
- C73-C75 Thyroid and other endocrine glands
- C76-C80 Malignant neoplasms of ill-defined, secondary and unspecified sites
- C81-C96 Malignant neoplasms of lymphoid, hematopoietic and related tissues that are designated as primary or suspected primary
- C97 Malignant neoplasms of independent (primary) multiple localizations
- D00-D09 In situ neoplasms
- D10-D36 Benign neoplasms
- D37-D48 Neoplasm of uncertain or unknown nature [see note on p. 242]
This class contains the following broad groups of neoplasms:
- C00-C97 Malignant neoplasms
- C00-C75 Malignant neoplasms of specified sites designated as primary or suspected primary, excluding neoplasms of lymphoid, hematopoietic and related tissues
- C00-C14 Lips, oral cavity and pharynx
- C15-C26 Digestive organs
- C30-C39 Respiratory and thoracic organs
- C40-C41 Bones and articular cartilage
- C45-C49 Mesothelial and soft tissues
- C50-C50 Breast
- C51-C58 Female reproductive organs
- C60-C63 Male reproductive organs
- C64-C68 Urinary tract
- C69-C72 Eyes, brain and other parts of the central nervous system
- C73-C75 Thyroid and other endocrine glands
- C76-C80 Malignant neoplasms of ill-defined, secondary and unspecified sites
- C81-C96 Malignant neoplasms of lymphoid, hematopoietic and related tissues that are designated as primary or suspected primary
- C97-C97 Malignant neoplasms of independent (primary) multiple sites
- C00-C75 Malignant neoplasms of specified sites designated as primary or suspected primary, excluding neoplasms of lymphoid, hematopoietic and related tissues
- D00-D09 In situ neoplasms
- D10-D36 Benign neoplasms
- D37-D48 Neoplasms of uncertain or unknown nature
Notes
Malignant neoplasms, primary, ill-defined and unspecified sites
Morphology
There are a number of large morphological (histological) groups of malignant neoplasms: caracinomas, including squamous and adenocarcinomas; sarcomas; other soft tissue tumors, including mesothelioma; lymphomas (Hodgkin's and non-Hodgkin's); leukemia; other refined and localization-specific types; unspecified cancers.
The term "cancer" is generic and can be used for any of the above groups, although it is rarely used in relation to malignant neoplasms of the lymphoid, hematopoietic and related tissues. The term "carcinoma" is sometimes incorrectly used as a synonym for the term "cancer".In class II, neoplasms are classified mainly by localization within broad groupings based on the nature of the course. In exceptional cases, morphology is indicated in the headings and subheadings.
For those wishing to identify the histological type of neoplasm, a general list of individual morphological codes is given. Morphological codes are taken from the second edition of the International Classification of Diseases in Oncology (ICD-O), which is a biaxial classification system that provides independent coding of neoplasms by topography and morphology.
Morphological codes have 6 characters, of which the first four determine the histological type, the fifth indicates the nature of the course of the tumor (malignant primary, malignant secondary, i.e. metastatic, in situ, benign, indefinite), and the sixth character determines the degree of differentiation of solid tumors and is also used as a special code for lymphomas and leukemias.
Use of subcategories in class II
Attention is drawn to the special use in this class of the subcategory marked.8 (see note 5). Where it is necessary to distinguish a subcategory for the group "others", a subcategory is usually used.7.
Malignant neoplasms extending beyond one site and the use of a subcategory with a fourth character.8 (lesion extending beyond one or more of the specified sites)
Use of the Alphabetical Index when coding neoplasms
When coding neoplasms, in addition to their localization, the morphology and nature of the course of the disease should be taken into account and, first of all, it is necessary to refer to the Alphabetical Index for a morphological description.
Use of the second edition of the International Classification of Diseases in Oncology (ICD-0)
For some morphological types, class II provides a rather narrow topographic classification, or none at all. ICD-0 topographical codes are used for all neoplasms with essentially the same three- and four-digit rubrics used in Class II for malignant neoplasms (C00-C77, C80), thereby providing greater localization accuracy for other neoplasms [malignant secondary ( metastatic), benign, in situ, uncertain or unknown].
Thus, institutions interested in determining the location and morphology of tumors (such as cancer registries, cancer hospitals, pathology departments, and other services specialized in oncology) should use ICD-0.
last modified: January 2016
If necessary, use an additional code (U85) to identify resistance, immunization, and refractive properties of the neoplasm to anticancer drugs.
last modified: January 2012
Note. Many in situ neoplasms are seen as successive morphological changes between dysplasia and invasive cancer. For example, three grades are recognized for cervical intraepithelial neoplasia (CIN), of which grade three (CIN III) includes both severe dysplasia and carcinoma in situ. This system of gradations is extended to other organs, such as the vulva and vagina. Descriptions of grade III intraepithelial neoplasia with or without indication of severe dysplasia are presented in this section; grades I and II are classified as dysplasias of the organ systems involved and should be coded to the classes corresponding to those organ systems.
Included:
- Bowen's disease
- erythroplasia
- morphological codes with the code of the nature of the neoplasm /2
- erythroplasia of Queira
Includes: morphological codes with behavioral code /0
Note. Categories D37-D48 are classified by location of neoplasms of uncertain or unknown nature (ie, neoplasms that raise doubts as to whether they are malignant or benign). In the classification of tumor morphology, such neoplasms are encoded by their nature with the code /1.
This class contains the following broad groups of neoplasms:
- C00-C97 Malignant neoplasms
- C00-C75 Malignant neoplasms of specified sites designated as primary or suspected primary, excluding neoplasms of lymphoid, hematopoietic and related tissues
- C00-C14 Lips, oral cavity and pharynx
- C15-C26 Digestive organs
- C30-C39 Respiratory and thoracic organs
- C40-C41 Bones and articular cartilage
- C45-C49 Mesothelial and soft tissues
- C50-C50 Breast
- C51-C58 Female reproductive organs
- C60-C63 Male reproductive organs
- C64-C68 Urinary tract
- C69-C72 Eyes, brain and other parts of the central nervous system
- C73-C75 Thyroid and other endocrine glands
- C76-C80 Malignant neoplasms of ill-defined, secondary and unspecified sites
- C81-C96 Malignant neoplasms of lymphoid, hematopoietic and related tissues that are designated as primary or suspected primary
- C97-C97 Malignant neoplasms of independent (primary) multiple sites
- C00-C75 Malignant neoplasms of specified sites designated as primary or suspected primary, excluding neoplasms of lymphoid, hematopoietic and related tissues
- D00-D09 In situ neoplasms
- D10-D36 Benign neoplasms
- D37-D48 Neoplasms of uncertain or unknown nature
Notes
Malignant neoplasms, primary, ill-defined and unspecified sites
Morphology
There are a number of large morphological (histological) groups of malignant neoplasms: caracinomas, including squamous and adenocarcinomas; sarcomas; other soft tissue tumors, including mesothelioma; lymphomas (Hodgkin's and non-Hodgkin's); leukemia; other refined and localization-specific types; unspecified cancers.
The term "cancer" is generic and can be used for any of the above groups, although it is rarely used in relation to malignant neoplasms of the lymphoid, hematopoietic and related tissues. The term "carcinoma" is sometimes incorrectly used as a synonym for the term "cancer".In class II, neoplasms are classified mainly by localization within broad groupings based on the nature of the course. In exceptional cases, morphology is indicated in the headings and subheadings.
For those wishing to identify the histological type of neoplasm, a general list of individual morphological codes is given. Morphological codes are taken from the second edition of the International Classification of Diseases in Oncology (ICD-O), which is a biaxial classification system that provides independent coding of neoplasms by topography and morphology.
Morphological codes have 6 characters, of which the first four determine the histological type, the fifth indicates the nature of the course of the tumor (malignant primary, malignant secondary, i.e. metastatic, in situ, benign, indefinite), and the sixth character determines the degree of differentiation of solid tumors and is also used as a special code for lymphomas and leukemias.
Use of subcategories in class II
Attention is drawn to the special use in this class of the subcategory marked.8 (see note 5). Where it is necessary to distinguish a subcategory for the group "others", a subcategory is usually used.7.
Malignant neoplasms extending beyond one site and the use of a subcategory with a fourth character.8 (lesion extending beyond one or more of the specified sites)
Use of the Alphabetical Index when coding neoplasms
When coding neoplasms, in addition to their localization, the morphology and nature of the course of the disease should be taken into account and, first of all, it is necessary to refer to the Alphabetical Index for a morphological description.
Use of the second edition of the International Classification of Diseases in Oncology (ICD-0)
For some morphological types, class II provides a rather narrow topographic classification, or none at all. ICD-0 topographical codes are used for all neoplasms with essentially the same three- and four-digit rubrics used in Class II for malignant neoplasms (C00-C77, C80), thereby providing greater localization accuracy for other neoplasms [malignant secondary ( metastatic), benign, in situ, uncertain or unknown].
Thus, institutions interested in determining the location and morphology of tumors (such as cancer registries, cancer hospitals, pathology departments, and other services specialized in oncology) should use ICD-0.
last modified: January 2016
If necessary, use an additional code (U85) to identify resistance, immunization, and refractive properties of the neoplasm to anticancer drugs.
last modified: January 2012
Note. Many in situ neoplasms are seen as successive morphological changes between dysplasia and invasive cancer. For example, three grades are recognized for cervical intraepithelial neoplasia (CIN), of which grade three (CIN III) includes both severe dysplasia and carcinoma in situ. This system of gradations is extended to other organs, such as the vulva and vagina. Descriptions of grade III intraepithelial neoplasia with or without indication of severe dysplasia are presented in this section; grades I and II are classified as dysplasias of the organ systems involved and should be coded to the classes corresponding to those organ systems.
Included:
- Bowen's disease
- erythroplasia
- morphological codes with the code of the nature of the neoplasm /2
- erythroplasia of Queira
Includes: morphological codes with behavioral code /0
Note. Categories D37-D48 are classified by location of neoplasms of uncertain or unknown nature (ie, neoplasms that raise doubts as to whether they are malignant or benign). In the classification of tumor morphology, such neoplasms are encoded by their nature with the code /1.
